Effects of ACE inhibitors on cardiac angiotensin II and aldosterone in humans: "Relevance of lipophilicity and affinity for ACE"

What Was Tested

Researchers studied Angiotensin II in this randomized controlled trial publication.

Angiotensin-converting enzyme (ACE) inhibitors differ in their lipophilic/hydrophilic index that determines their tissue bioavailability and affinity to ACE, which may result in major differences in the degree of blockade of cardiac ACE.

The researchers evaluated the hypothesis that in patients with chronic heart failure (CHF) and activated cardiac renin-angiotensin-aldosterone system (RAAS), lipophilic ACE inhibitors with high affinity for ACE (perindopril and quinapril) will cause marked blockade of cardiac angiotensin (Ang) II and aldosterone generation, but not a hydrophilic ACE inhibitor with low affinity for ACE (lisinopril).

Who Took Part

By PubMed's age tags, the people studied were young adults, adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got Angiotensin II and who got the comparison, which limits bias.

The coronary sinus-aortic root gradients for Ang I and II, and aldosterone were determined.

What Was Measured

The researchers evaluated the hypothesis that in patients with chronic heart failure (CHF) and activated cardiac renin-angiotensin-aldosterone system (RAAS), lipophilic ACE inhibitors with high affinity for ACE (perindopril and quinapril) will cause marked blockade of cardiac angiotensin (Ang) II and aldosterone generation, but not a hydrophilic ACE inhibitor with low affinity for ACE (lisinopril).

The subject headings attached to it are Aldosterone, Angiotensin II, Angiotensin-Converting Enzyme Inhibitors, Aorta, Thoracic, Cardiac Catheterization, Coronary Sinus and Hydrophobic and Hydrophilic Interactions.

What This Means in Plain Language

The paper is a randomized study of Angiotensin II.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2010 (American journal of hypertension), a journal based in United States.

More context: the Angiotensin II compound page, all human trials.